Navigation Links
US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
Date:5/26/2011

THE WOODLANDS, Texas, May 26, 2011 /PRNewswire/ -- McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, announced today that four physicians affiliated with US Oncology Research and the United Network of US Oncology will give oral presentations at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3 - 7 at McCormick Place in Chicago.

ASCO is the world's leading professional organization representing physicians who care for people with cancer. More than 70 McKesson Specialty Care Solutions | US Oncology affiliated oncology experts have contributed to more than 60 studies being featured at this year's major medical meeting.

"US Oncology Research affiliated investigators are consistently on the cutting edge when it comes to the life-changing therapies of the future," said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2011 ASCO Annual Meeting. "When it comes to advancing cancer care, these investigators are contributing in a major way. Take the MEK inhibitor study for example. The investigators understand molecular mechanisms, work with companies which have drugs targeting those mechanisms and use them to successfully treat patients in their practices. This is translational research at its best."The four studies being presented orally at ASCO by US Oncology Research affiliated physicians are as follows:Frankie Ann Holmes, MD, Texas OncologySunday, June 5, 9:45 AM - 10:00 AM, Hall B1


  • Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.John Pippen, MD, FACP, Texas OncologySunday, June 5, 4:30 PM - 4:45 PM, Hall B1


  • Randomized, phase III study of adjuvant doxorubicin + cyclophosphamide (AC) --> docetaxel (T) +/- capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses.Joyce O'Shaughnessy, MD, Texas OncologyMonday, June 6, 11:00 AM - 11:15 AM, Hall B1


  • A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).Robert Jotte, MD, PhD, Rocky Mountain Cancer CentersTuesday, June 7, 8:00 AM - 8:15 AM, Arie Crown Theater


  • Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC)."Studies such as these are leading to advances in treating cancer," said John Pippen, MD, FACP, Texas Oncology. "Our US Oncology clinical trials lead to approval of new drugs, better treatment combinations, and better prediction of whether a patient will benefit from a particular cancer treatment."

    In addition to these oral presentations, Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology, will be speaking during an education session on the management of unique subsets of patients with renal cell cancer. This session takes place on Sunday, June 5 in Hall D2 from 11:30 AM – 12:45 PM.

    US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

    Other presentations that McKesson Specialty Care Solutions | US Oncology affiliated investigators are part of include:

    Oral Presentations:Thomas Cartwright, MD, Ocala Oncology CenterSaturday, June 4, 2:45 PM – 3:00 PM, Hall D1


  • A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologySaturday, June 4, 4:00 PM – 4:15 PM, Arie Crown Theater


  • BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.Michael Teneriello, MD, FACOG, Texas OncologySaturday, June 4, 4:15 PM - 4:30 PM, E354a

  • OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).Jerome Goldschmidt, MD, Blue Ridge Cancer CareSunday, June 5, 10:00 AM - 10:15 AM, Hall D1


  • Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with Erlotinib in advanced NSCLC.Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchSunday, June 5, 11:00 AM - 11:15 AM, Arie Crown Theater


  • Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologySunday, June 5, 11:50 AM - 12:10 PM, Hall D2


  • Management of Unique Subsets of Patients with Renal Cell Cancer.Nicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaAlexander Spira, MD, Virginia Cancer SpecialistsSunday, June 5, 12:00 PM - 12:15 PM, Arie Crown Theater


  • Cabozantinib (XL184) has activity in both soft tissue & bone: Results of a phase 2 randomized discontinuation trial (RDT) in patients (pts) w/ advanced solid tumors.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyMonday, June 6, 8:00 AM - 8:15 AM, Hall D2


  • Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.Jeff Sharman, MD, Willamette Valley Cancer Institute and Research CenterDonald Richards, MD, PhD, Texas OncologyMonday, June 6, 9:30 AM - 12:30 PM, Arie Crown Theater


  • Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.Alexander Spira, MD, Virginia Cancer SpecialistsNicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaMonday, June 6, 1:15 PM - 1:30 PM, Hall D1


  • Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.Poster Discussions:Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #23

    Saturday, June 4, 8:00 AM – 12:00 PM, S403 Discussion

    12:00 PM – 1:00 PM, S406


  • Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #5

    Saturday, June 4, 2:00 PM - 6:00 PM, S403Discussion

    5:00 PM - 6:00 PM, S406


  • Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.Guru Sonpavde, MD, Texas OncologyMark Fleming, MD, Virginia Oncology AssociatesThomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #8

    Saturday, June 4, 2:00 PM - 6:00 PM, E450aDiscussion

    5:00 PM - 6:00 PM, Hall D


  • A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC).Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #17

    Saturday, June 4, 2:00 PM - 6:00 PM, S103Discussion

    5:00 PM - 6:00 PM, S100bc


  • Circulating protein biomarkers of sunitinib and interferon efficacy in treatment naive patients with metastatic renal cell carcinoma.Carlos Becerra, MD, Texas OncologyPoster #14

    Monday, June 6, 8:00 AM - 12:00 PM, E450bDiscussion

    11:30 AM - 12:30 PM, Hall D1


  • Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).Donald Richards, MD, PhD, Texas OncologyDarren M Kocs, MD, Texas OncologyAlexander Spira, MD, Virginia Cancer SpecialistsDavid McCollum, MD, Texas OncologyKristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology ResearchPoster #8

    Monday, June 6, 2:00 PM - 6:00 PM, E450bDiscussion

    5:00 PM - 6:00 PM, Hall D1


  • Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study.Donald Richards, MD, PhD, Texas OncologyPoster #11

    Monday, June 6, 2:00 PM - 6:00 PM, E450bDiscussion

    5:00 PM - 6:00 PM, Hall D1


  • Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.Guru Sonpavde, MD, Texas OncologyNicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaPeter Rosen, MD, Roy & Patricia Disney Cancer Research CenterAlexander Spira, MD, Virginia Cancer SpecialistsPoster #22

    Tuesday, June 7, 8:00 AM - 12:00 PM, E450bDiscussion

    11:30 AM - 12:30 PM, E354a


  • Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).Posters:Joyce O'Shaughnessy, MD, Texas OncologyThomas Cartwright, MD, Ocala Oncology CenterPoster #21C

    Saturday, June 4, 8:00 AM - 12:00 PM, Hall A


  • Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer.Joe Stephenson, MD, Cancer Centers of the CarolinasDonald Richards, MD, PhD, Texas OncologyCarlos Becerra, MD, Texas OncologyPoster #36H

    Saturday, June 4, 8:00 AM - 12:00 PM, Hall A


  • The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.Nicholas Robert, MD, Virginia Cancer SpecialistsPoster #43C

    Saturday, June 4, 8:00 AM - 12:00 PM, Hall A


  • Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).Craig Reynolds, MD, Ocala Oncology CenterAlexander Spira, MD, Virginia Cancer SpecialistsLarry Gluck, MD, Cancer Centers of the CarolinasRobert Pluenneke, MD, Kansas City Cancer CentersKristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology ResearchPoster #33E

    Saturday, June 4, 2:00 PM - 6:00 PM, Hall A


  • Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.Ruth Oratz, MD, FACP, The Women's Oncology & Wellness PracticePoster #1B

    Saturday, June 4, 2:00 PM - 6:00 PM, Hall A


  • Recruitment in the internet era: An efficient strategy for studying breast cancer risk.Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #9F

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • A phase I dose escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.William Berry, MD, Cancer Centers of North CarolinaGuru Sonpavde, MD, Texas OncologyPoster #2E

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).Guru Sonpavde, MD, Texas OncologyPoster #2F

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC).Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #5D

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #6B

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • Analysis of the relationship between KPS and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma.Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #9A

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • Very low incidence of thyroid dysfunction in renal cell carcinoma patiens treated with pazopanib in prospective clinical trials.Guru Sonpavde, MD, Texas OncologyPoster #13F

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A


  • Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).Michael Teneriello, MD, FACOG, Texas OncologyJohn R. Caton, MD, Willamette Valley Cancer Institute and Research CenterRobert H. Gersh, MD, Cancer Care NorthwestPoster #15A

    Sunday, June 5, 8:00 AM - 12:00 PM, Hall A

  • PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #16A

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • First in human study with ARQ 621, a novel inhibitor of Eg5: final results from the solid tumors cohort.Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #17D

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.Stephen Anthony, DO, Evergreen Hematology and OncologyDaniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology ResearchPoster #18B

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.Kavita Sail, MS, PhD, Healthcare Informatics, US OncologyMelissa Halm, MPH, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyPoster #12B

    Monday, June 6, 1:00 PM - 5:00 PM, Hall A


  • Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab-containing regimen.Clara Chen, MS, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersDenise Kazzaz, Jeff Shankleton, Ramachandran Ganesh, Healthcare Informatics, US OncologyPoster #12C

    Monday, June 6, 1:00 PM - 5:00 PM, Hall A


  • Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer.Nicholas Robert, MD, Virginia Cancer SpecialistsJoyce O'Shaughnessy, MD, Texas OncologyPoster #19E

    Monday, June 6, 1:00 PM - 5:00 PM, Hall A


  • Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).Karen Tedesco, MD, New York Oncology HematologyJoanne Blum, MD, Texas OncologyCynthia Osborne, MD, Texas OncologyFrankie Ann Holmes, MD, Texas OncologyPoster #25B

    Monday, June 6, 1:00 PM - 5:00 PM, Hall A


  • Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).Robert Rifkin, MD, FACP, Rocky Mountain Cancer CentersPoster #48D

    Monday, June 6, 1:00 PM - 5:00 PM, Hall A


  • Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma patients ineligible for transplant in the phase 3b UPFRONT study.Trials in Progress:Joanne Blum, MD, Texas OncologyPoster #37D

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive-(ER+) breast cancer.Allen Cohn, MD, Rocky Mountain Cancer CentersLinda DeMarco, MD, FACP, New York Oncology HematologyJean Stephenson, RN, Texas OncologyBrian Ulrich, MD, Texas OncologyPeter Yu, MD, Camino Medical GroupPoster #45F

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 vs gemcitabine alone in previously untreated patients with advanced pancreatic cancer.Frankie Ann Holmes, MD, Texas OncologyPoster #40G

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • A phase 3 trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).Thomas E. Hutson, DO, PharmD, FACP, Texas OncologyPoster #47H

    Monday, June 6, 8:00 AM - 12:00 PM, Hall A


  • Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.Publish Only:Joyce O'Shaughnessy, MD, Texas Oncology


  • Eribulin mesylate EMBRACE study: Survival analysis excluding patients rechallenged with therapies of the same class.Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


  • Phase III study of axitinib versus sorafenib for treatment of patients with metastatic renal cell carcinoma.  TRIAL in PROGRESS.William Berry, MD, Cancer Centers of North CarolinaMark Fleming, MD, Virginia Oncology AssociatesMichael Kolodziej, MD, New York Oncology HematologySanjiv Awasthi, Texas OncologyThomas E. Hutson, DO, PharmD, FACP, Texas OncologyDanko Martincic, MD, Cancer Care NorthwestGuru Sonpavde, MD, Texas OncologyYunfei Wang, Lina Asmar, PhD, US Oncology Research


  • Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.Nicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaPaul Conkling, MD, Virginia Oncology AssociatesManuel Modiano, MD, Arizona Oncology Associates


  • An open-label, multicenter, randomized Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine plus cisplatin versus gemcitabine plus cisplatin alone as first line therapy for locally advanced or metastatic bladder cancer.Marcus Neubauer, MD, Jody S. Garey, PharmD, Greg Nelson, Debra Patt, MD, Tom Cartwright, MD, Russ Hoverman, MD, Leslie T. Busby, MD, Barry Brooks, MD, Mark Sitarik, MD, Mike Kolodziej, MD, Roger Anderson Dr PH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team


  • Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC):  outcomes from a community oncology network.Mark Fleming, MD, Virginia Oncology AssociatesJohn Burke, MD, Rocky Mountain Cancer CentersJohn R. Caton, MD, Willamette Valley Cancer Institute and Research CenterGuru Sonpavde, MD, Texas Oncology


  • Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).Aimee L. Ginsburg, PharmD, Debra M. Patt MD, Jennifer Flinn, Janet L. Espirito, PharmD, Marcus A. Neubauer, MD, J. Russell Hoverman, MD, PhD, Thomas H. Cartwright, MD, Leslie T. Busby, MD, Barry Don Brooks, MD, Michael A. Kolodziej, MD, Mark A. Sitarik, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team


  • Understanding Male Breast Cancer in the Community Setting.Debra Patt, MD, Janet Espirito, PharmD, Brian Turnwald, J. Russell Hoverman, MD, Marcus Neubauer, MD, Thomas Cartwright, MD, Barry Brooks, MD, Leslie Busby, MD, Mark Sitarik, MD, Michael Kolodziej, MD, Aimee Ginsburg, PharmD, Sheetal Sheth, PharmD, Jody Garey, PharmD, Matthew Clayton, Greg Nelson, Roger Anderson, DrPH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team


  • Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community.Avani Joshi, PhD, Healthcare Informatics, US OncologyDavid Fryefield, MD, Willamette Valley Cancer Institute and Research CenterMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersWilliam Lopez, Healthcare Informatics, US Oncology


  • Demographic and treatment characteristics for advanced basal cell carcinoma (aBCC) in an oncology outpatient setting.Thomas Cartwright, MD, Ocala Oncology CenterMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersHeather Hartnett, PhD, Hsingwen Chung, MS, Melissa Halm, MPH, Healthcare Informatics, US Oncology


  • mCRC - Survival Outcomes with the use of Bevacizumab beyond progression in metastatic colorectal cancer patients.Clara Chen, MS, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersDenise Kazzaz, Jeff Shankleton, Ramachandran Ganesh, Healthcare Informatics, US Oncology


  • Evaluation of relation between Oncotype DX recurrence score and adjuvant chemotherapy administration.Kavita Sail, MS, PhD, Healthcare Informatics, US OncologyDebra Patt, MD, MPH, Texas OncologyMichael Forsyth, RPh, MBA, Rocky Mountain Cancer CentersMelissa Halm, MPH, William Lopez, Healthcare Informatics, US Oncology


  • Patterns of Care and Patient Characteristics in Post-menopausal Women with HER2+ and Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC).Dean Gesme, MD, FACP, FACPE, Minnesota Oncology


  • Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.Joanne Blum, MD, Texas Oncology


  • Capecitabine (Cap) monotherapy in anthracycline (A)-/taxane – (T) pretreated MBC.Presentations from McKesson:Poster:Zhaohui Wang, McKesson Specialty Care SolutionsPoster #32B

    Saturday, June 4, 2:00 PM – 6:00 PM, Hall A


  • Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices.Publish Only:Brandon Tom, McKesson Corporation


  • Leveraging technology and data to facilitate development of cost-effective pathways.About McKesson Specialty Care Solutions | US OncologyMcKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckesson.com/specialty and www.usoncology.com.

    About US Oncology ResearchMcKesson Specialty Care Solutions | US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary uniting one of the nation's largest community-based cancer research networks. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 95 sites in 225 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 48,000 patients in more than 1,150 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

    About Healthcare InformaticsMcKesson Specialty Care Solutions | US Oncology integrates oncology expertise and business insight through its Healthcare Informatics program to provide real-world, evidence-based market intelligence for managing a drug therapy's lifecycle. Comprehensive cancer care data assets such as electronic health records (EHRs), claims, specialties, reimbursement, and sales data provide unparalleled insight into the oncology marketplace to drive and develop successful commercialization strategies. The Healthcare Informatics group includes outcomes researchers, clinical data analysts, pharmacists, and biostatisticians who provide clinical and economic expertise to guide strategic branding and business decisions for the oncology industry. For more information, please call (866) 951-2774 or email bpsg@usoncology.com.


    '/>"/>

  • SOURCE US Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
    3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
    5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
    6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
    7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
    8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
    9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
    10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
    11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
    (Date:2/4/2016)... 2016  Aethlon Medical, Inc. (Nasdaq: AEMD ... to treat life-threatening diseases, today announced results for ... 31, 2015. --> ... in our last quarterly call, we strategically advanced ... objective to establish the Aethlon Hemopurifier® as a ...
    (Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
    Breaking Medicine Technology:
    (Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
    (Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
    (Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
    (Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
    Breaking Medicine News(10 mins):